Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 2
2005 5
2006 2
2007 3
2008 2
2009 5
2010 3
2011 11
2012 13
2013 14
2014 10
2015 13
2016 8
2017 9
2018 26
2019 39
2020 43
2021 50
2022 29
2023 33
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

290 results

Results by year

Filters applied: . Clear all
Page 1
JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analog suppressed patients with chronic hepatitis B: REEF-2.
Agarwal K, Buti M, van Bömmel F, Lampertico P, Janczewska E, Bourliere M, Vanwolleghem T, Lenz O, Verbinnen T, Kakuda TN, Mayer C, Jezorwski J, Muenz D, Beumont M, Kalmeijer R, Biermer M, Lonjon-Domanec I. Agarwal K, et al. Among authors: lampertico p. J Hepatol. 2024 Apr 5:S0168-8278(24)00231-9. doi: 10.1016/j.jhep.2024.03.046. Online ahead of print. J Hepatol. 2024. PMID: 38583491 Free article.
Comprehensive investigation of platelet function in patients with cirrhosis.
Lecchi A, Tosetti G, Ghali C, La Marca S, Clerici M, Padovan L, Femia EA, Primignani M, La Mura V, Lampertico P, Peyvandi F, Tripodi A. Lecchi A, et al. Among authors: lampertico p. Thromb Res. 2024 May;237:64-70. doi: 10.1016/j.thromres.2024.03.017. Epub 2024 Mar 16. Thromb Res. 2024. PMID: 38552496
Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis-A real-world case series.
Dietz-Fricke C, Degasperi E, Jachs M, Maasoumy B, Reiter FP, Geier A, Grottenthaler JM, Berg CP, Sprinzl K, Zeuzem S, Gödiker J, Schlevogt B, Herta T, Wiegand J, Soffredini R, Wedemeyer H, Deterding K, Reiberger T, Lampertico P. Dietz-Fricke C, et al. Among authors: lampertico p. Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000847. Online ahead of print. Hepatology. 2024. PMID: 38478755
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Mangia A, Pericàs JM, Patil R, Sanyal AJ, Noureddin M, Bansal MB, Alkhouri N, Castera L, Rudraraju M, Ratziu V; MAESTRO-NASH Investigators. Harrison SA, et al. N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000. N Engl J Med. 2024. PMID: 38324483 Clinical Trial.
Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations.
Shekhtman L, Cotler SJ, Degasperi E, Anolli MP, Uceda Renteria SC, Sambarino D, Borghi M, Perbellini R, Facchetti F, Ceriotti F, Lampertico P, Dahari H. Shekhtman L, et al. Among authors: lampertico p. JHEP Rep. 2023 Nov 15;6(2):100966. doi: 10.1016/j.jhepr.2023.100966. eCollection 2024 Feb. JHEP Rep. 2023. PMID: 38274491 Free PMC article.
290 results